GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Marksans Pharma Ltd

Marksans Pharma Q2 FY27 Standalone Revenue up to Rs. 9,906.19 million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 01:35 PM IST  ·  BSE ID: 3b74e82f-f6f0-4897-b801-15ed146e4cee
View Original BSE Filing (PDF)
💡
In Simple Terms
Marksans Pharma released its Q2 financial results, showing significant revenue and profit increases for the quarter and half year.
🤖 AI Summary
  • Marksans Pharma reported standalone revenue from operations of Rs. 9,906.19 million for Q2 FY27.
  • Standalone profit before tax for the half year ended 30 September 2026 was Rs. 1,906.71 million.
  • The Board of Directors approved the unaudited standalone financial results on November 04, 2026.
  • M/s. MSKA & Associates LLP provided an unmodified limited review report on the financial results.
  • During H1 FY27, Marksans Pharma acquired 100% share capital of QliniQ B.V. for EUR 7.50 Million.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Standalone) Q2 FY27
Rs. 9,906.19 million
Not comparable — limited prior period data.
Profit Before Tax (Standalone) Half Year ended 30 September 2026
Rs. 1,906.71 million
3.03%
Net Cash Generated from Operating Activities (Standalone) Half Year ended 30 September 2026
Rs. 1,852.16 million
901.93%
Cash and Cash Equivalents (Standalone) at 30 September 2026
Rs. 1,389.09 million
70.0%+
🏢 How This Affects the Company
📈
Business Impact
The acquisitions of QliniQ B.V. and ABCnow GmbH indicate expansion into the Dutch and German healthcare markets, enhancing marketing and distribution capabilities for prescription medicines and medical devices.
💰
Financial Impact
Net cash generated from operating activities for the half year ended 30 September 2026 increased to Rs. 1,852.16 million from Rs. 184.86 million in the prior comparable period. Cash and cash equivalents at period end grew to Rs. 1,389.09 million from Rs. 817.31 million.
⚙️
Operational Impact
The acquisition of ABCnow GmbH adds frontend sales, marketing, and distribution capabilities in Germany, which could integrate with existing operations.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and strategic acquisitions, as these factors influence the company's value.
🔍
Management Signal
Management is focused on both organic growth through financial performance and inorganic expansion through strategic acquisitions in key European markets.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor sustained growth in revenue and cash from operations.
Updates on integration of QliniQ B.V. and ABCnow GmbH acquisitions.
Details on future capital allocation for property, plant, and equipment.
LOW RISK The filing indicates strong operational cash flow and strategic acquisitions without flaggable concerns.
💡 Investor Takeaway
Marksans Pharma reported standalone revenue from operations of Rs. 9,906.19 million for Q2 FY27 and a profit before tax of Rs. 1,906.71 million for H1 FY27. Net cash from operations significantly improved to Rs. 1,852.16 million for H1 FY27.
⚖️ Strengths & Concerns

✅ Positives

  • Net cash generated from operating activities for H1 FY27 rose substantially to Rs. 1,852.16 million from Rs. 184.86 million.
  • Cash and cash equivalents increased to Rs. 1,389.09 million at 30 September 2026 from Rs. 817.31 million in the prior year.
📅 Company Track Record
Marksans Pharma's Q2 FY27 standalone revenue of Rs. 9,906.19 million follows a reported consolidated revenue of Rs. 940.2 crore (Rs. 9,402 million) for the same quarter as per a related press release. The company had reported audited FY26 results with a Profit After Tax of Rs. 3,006.98 million.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Marksans Pharma's standalone revenue from operations for Q2 FY27?
Marksans Pharma reported a standalone revenue from operations of Rs. 9,906.19 million for the quarter ended 30 September 2026 (Q2 FY27).
What was Marksans Pharma's standalone profit before tax for the half year ended 30 September 2026?
The standalone profit before tax for Marksans Pharma for the half year ended 30 September 2026 was Rs. 1,906.71 million, compared to Rs. 1,850.67 million for the previous comparable half year.
How much cash did Marksans Pharma generate from operating activities in H1 FY27?
Net cash generated from standalone operating activities for Marksans Pharma was Rs. 1,852.16 million for the half year ended 30 September 2026, compared to Rs. 184.86 million in the prior year.
What acquisitions did Marksans Pharma complete in H1 FY27?
During H1 FY27, Marksans Pharma acquired 100% share capital of QliniQ B.V. (Netherlands) for EUR 7.50 Million and ABCnow GmbH (Germany) for EUR 1.10 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.